<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109577</url>
  </required_header>
  <id_info>
    <org_study_id>18229</org_study_id>
    <secondary_id>AIS99-03A (01406-005-23)</secondary_id>
    <nct_id>NCT00109577</nct_id>
  </id_info>
  <brief_title>Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder</brief_title>
  <official_title>Randomized Placebo-controlled Phase II Trial of MCN36 in Adults With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Innovation and Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement
      (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when
      studied under randomized and fully blinded conditions and compared to a placebo. The
      supplement is referred to as MCN36, because it contains 36 nutrients. Based on the
      preliminary research on this supplement, it is hypothesized that patients who take MCN36 for
      8 weeks will experience improved mood stability relative to those who take the placebo. All
      participants must live EITHER in the vicinity of Calgary, Alberta, Canada, OR in the area of
      San Diego, California.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This RCT (randomized clinical trial) compared MCN36 to placebo in patients randomized to
      receive one or the other for 8 weeks. Close medical supervision was provided with weekly
      appointments. At the end of the 8 weeks, all participants were offered the opportunity of
      entering an 8-week open-label extension.

      The efficacy objective of this study was to assess the efficacy of MCN36 compared with
      placebo in otherwise medication-free adults with bipolar disorder I and II, in improving
      overall symptomatology at the end of 8 weeks of therapy as assessed under randomized and
      fully blinded conditions

        -  as measured by the clinician using the Overall Bipolarity Index (OBI) (primary outcome
           measure).

        -  as measured by the clinician using the Clinical Global Impressions for Bipolar Disorder
           (CGI-BP) for Severity.

        -  as measured by self-report recorded on the Outcome Questionnaire (OQ).

        -  in terms of rate of response, with response defined as a reduction of 50% or more in
           either the depression or the mood elevation component of the OBI.

        -  in terms of functional states and health-related quality of life as measured by The
           Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).

      The safety-related objective was to assess the safety of MCN36 compared with placebo in terms
      of

        -  laboratory analyses

        -  treatment-emergent adverse events, which will be solicited at each appointment using the
           Adverse Event Log.

      Participants had two appointments for screening and confirming suitability for the trial.
      Between those two appointments, they provided a blood sample, and met with a research nurse.
      They also kept a 7-day food record of their food intake prior to the second appointment. If
      suitability was confirmed at the second visit, they entered the randomized phase.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit large enough sample; large expectancy effects but no adverse events
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mood as Evaluated by the Overall Bipolarity Index (Composite of the Hamilton Depression Scale and the Young Mania Rating Scale)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in mood from baseline to final visit, as evaluated by the Overall Bipolarity Index (composite of the Hamilton Depression Scale and the Young Mania Rating Scale); minimum possible score is 0 and maximum possible score is 103; higher scores mean worse symptomatology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Clinical Impressions</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Questionnaire --- a Self-report Questionnaire</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator, 6 placebo capsules three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCN36 (nutritional supplement)</intervention_name>
    <description>nutritional supplement</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>nutritional supplement</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must meet the criteria for bipolar disorder I or II as defined in DSM-IV-TR based on
             clinical assessment and confirmed by structured diagnostic interview (SCID-P).

          -  Must be symptomatic on the Hamilton Depression Scale and the Young Mania Rating Scale

          -  Must be free of medications or herbal/nutritional supplements with primarily central
             nervous system activity

          -  Must be able to eat at least a snack three times per day, so that the capsules will
             not be ingested on an empty stomach

        Exclusion Criteria:

          -  Current or lifetime diagnosis of any of the following according to DSM-IV-TR criteria:
             Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional
             Disorder, Psychotic Disorder Not Otherwise Specified, Delirium of any type, Dementia
             of any type, Amnestic Disorder, unless there is substantive reason to believe the
             patient was misdiagnosed.

          -  Alcohol dependence or abuse in the previous six months.

          -  Dependence or abuse of substances other than alcohol in the previous two years.

          -  Any Psychotic Disorder due to a General Medical Condition in the previous two years

          -  Hospitalization for treatment of a mental disorder within the previous 6 months.

          -  Current use of any other medication or herbal/nutritional supplement with primarily
             central nervous system activity.

          -  Neurological disorder involving brain or other central function.

          -  Severe headaches of any type (including migraine) within the previous 3 months.

          -  Unstable illnesses either with active significant symptoms or requiring medication
             changes within the previous 4 months.

          -  Abnormal laboratory values detected at screening, in particular an ALT or AST greater
             than 2 times the upper limit of normal, or creatinine greater than 1.75 times the
             upper limit of normal.

          -  Uncorrected or unstable hypothyroidism or hyperthyroidism in the previous 12 months.

          -  Medically diagnosed Irritable Bowel Syndrome, or any other chronic gastrointestinal
             problem, within the previous 3 years.

          -  Current or lifetime metabolic disorder or problem, such as phenylketonuria or Wilson's
             disease.

          -  A course of treatment with electroconvulsive therapy (ECT) within the previous 12
             months, or a lifetime history of four or more courses of ECT.

          -  Current bacterial, viral, fungal, parasite or other infection.

          -  Women who are pregnant or breast-feeding; women of childbearing potential who are not
             using a medically accepted means of contraception when engaging in sexual intercourse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonnie J Kaplan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Estelle Goldstein</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Faculty of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaplan BJ, Simpson JS, Ferre RC, Gorman CP, McMullen DM, Crawford SG. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. J Clin Psychiatry. 2001 Dec;62(12):936-44.</citation>
    <PMID>11780873</PMID>
  </reference>
  <reference>
    <citation>Kaplan BJ, Fisher JE, Crawford SG, Field CJ, Kolb B. Improved mood and behavior during treatment with a mineral-vitamin supplement: an open-label case series of children. J Child Adolesc Psychopharmacol. 2004 Spring;14(1):115-22.</citation>
    <PMID>15142398</PMID>
  </reference>
  <reference>
    <citation>Kaplan BJ, Crawford SG, Gardner B, Farrelly G. Treatment of mood lability and explosive rage with minerals and vitamins: two case studies in children. J Child Adolesc Psychopharmacol. 2002 Fall;12(3):205-19.</citation>
    <PMID>12427294</PMID>
  </reference>
  <reference>
    <citation>Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? J Clin Psychiatry. 2001 Dec;62(12):933-5.</citation>
    <PMID>11780872</PMID>
  </reference>
  <reference>
    <citation>Simmons M. Nutritional approach to bipolar disorder. J Clin Psychiatry. 2003 Mar;64(3):338; author reply 338-9.</citation>
    <PMID>12716280</PMID>
  </reference>
  <reference>
    <citation>Kaplan BJ, Crawford SG, Field CJ, Simpson JS. Vitamins, minerals, and mood. Psychol Bull. 2007 Sep;133(5):747-60. Review.</citation>
    <PMID>17723028</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2005</study_first_submitted>
  <study_first_submitted_qc>April 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2005</study_first_posted>
  <results_first_submitted>June 25, 2012</results_first_submitted>
  <results_first_submitted_qc>August 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 11, 2012</results_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Bonnie Kaplan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>bipolar disorder</keyword>
  <keyword>mood disorders</keyword>
  <keyword>manic depression</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Comparator</title>
          <description>Placebo comparator capsules</description>
        </group>
        <group group_id="P2">
          <title>Micronutrient Formula</title>
          <description>nutritional supplement capsules containing 36-ingredients primarily vitamins and minerals; the supplement is referred to as MCN36, because it contains 36 nutrients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Comparator</title>
          <description>Placebo comparator</description>
        </group>
        <group group_id="B2">
          <title>Micronutrient Formula</title>
          <description>nutritional supplement</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="13"/>
                    <measurement group_id="B2" value="35" spread="9"/>
                    <measurement group_id="B3" value="37.5" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mood as Evaluated by the Overall Bipolarity Index (Composite of the Hamilton Depression Scale and the Young Mania Rating Scale)</title>
        <description>Change in mood from baseline to final visit, as evaluated by the Overall Bipolarity Index (composite of the Hamilton Depression Scale and the Young Mania Rating Scale); minimum possible score is 0 and maximum possible score is 103; higher scores mean worse symptomatology</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>All participants were included, since the analysis was intent-to-treat with last observation carried forward</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator</title>
            <description>Placebo comparator capsules</description>
          </group>
          <group group_id="O2">
            <title>Micronutrient Formula</title>
            <description>nutritional supplement capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Mood as Evaluated by the Overall Bipolarity Index (Composite of the Hamilton Depression Scale and the Young Mania Rating Scale)</title>
          <description>Change in mood from baseline to final visit, as evaluated by the Overall Bipolarity Index (composite of the Hamilton Depression Scale and the Young Mania Rating Scale); minimum possible score is 0 and maximum possible score is 103; higher scores mean worse symptomatology</description>
          <population>All participants were included, since the analysis was intent-to-treat with last observation carried forward</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" spread="3.4"/>
                    <measurement group_id="O2" value="-18.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Clinical Impressions</title>
        <time_frame>Baseline to 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Questionnaire --- a Self-report Questionnaire</title>
        <time_frame>Baseline to 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)</title>
        <time_frame>Baseline to 8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Comparator</title>
          <description>Placebo comparator</description>
        </group>
        <group group_id="E2">
          <title>Micronutrient Formula</title>
          <description>nutritional supplement</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bonnie Kaplan</name_or_title>
      <organization>University of Calgary</organization>
      <phone>403-955-7363</phone>
      <email>kaplan@ucalgary.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

